ArticleFrontiers in oncology2026
Prognostic impact of early disease progression and early mortality in patients with multiple myeloma: a real-world cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple myeloma (MM) is a clinically heterogeneous malignancy in which outcomes remain difficult to predict using static baseline risk models. Increasing attention has shifted toward dynamic prognostic markers, including early disease progression and early mortality; however, their relative prognostic value-particularly the optimal definition of early progression-and their integration with patient-related factors remain insufficiently defined in real-world populations. Methods: We retrospectively analysed 207 newly diagnosed MM patients treated between 2018 and 2023. Early disease progression was defined as progression within 18 (POD18) and 24 months (POD24) from treatment initiation. Early mortality was defined as death within six months of diagnosis. Overall survival (OS) and progression-free survival (PFS) were analysed using Kaplan-Meier estimates and Cox regression models, including time-dependent analyses. Results: During a median follow-up of 60 months, POD18 occurred in 44.0% and POD24 in 51.2% of patients. POD18 was strongly associated with inferior OS (HR 9.38; 95% CI 5.98-14.70; p < 0.0001) and demonstrated superior prognostic discrimination compared with POD24 (C-index 0.742 vs. 0.719). In multivariable analysis, POD18 remained the strongest independent predictor of OS, alongside comorbidity burden and performance status. Early mortality occurred in 17.9% of patients and was independently associated with advanced disease stage. Time-dependent modelling showed that the prognostic impact of baseline staging decreased over time, supporting the dynamic nature of risk in MM. Conclusion: POD18 is a robust and clinically informative dynamic prognostic marker that outperforms POD24 in predicting survival in real-world patients with MM. Integration of early disease kinetics with baseline disease burden and comorbidity burden provides a pragmatic framework for dynamic risk stratification, particularly in settings with limited access to comprehensive molecular profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.